Amplatzer Amulet Left Atrial Appendage Occluder Model Numbers 1. 9-ACP2-007-016 2. 9-ACP2-007-018 3. 9-ACP2-007-020 4. 9-ACP2-007-022 5. 9-ACP2-010-025 6. 9-ACP2-010-028 7. 9-ACP2-010-031 8. 9-ACP2-010-034 Recall
Amplatzer Amulet Left Atrial Appendage Occluder Model Numbers 1. 9-ACP2-007-016 2. 9-ACP2-007-018 3. 9-ACP2-007-020 4. 9-ACP2-007-022 5. 9-ACP2-010-025 6. 9-ACP2-010-028 7. 9-ACP2-010-031 8. 9-ACP2-010-034
FDA recall Class II
Ongoing
FDA lists this Class II recall for Amplatzer Amulet Left Atrial Appendage Occluder Model Numbers 1. 9-ACP2-007-016 2. 9-ACP2-007-018 3. 9-ACP2-007-020 4. 9-ACP2-007-022 5. 9-ACP2-010-025 6. 9-ACP2-010-028 7. 9-ACP2-010-031 8. 9-ACP2-010-034. Review the affected identifiers, reported reason and manufacturer instructions below.
Recall at a glance
- Recall number
- Z-0191-2027
- Recall classification
- Class II
- Enforcement status
- Ongoing
- Initiation date
- Sep 10, 2026
- FDA report date
- Oct 28, 2026
- Quantity in commerce
- Not reported
- Distribution
- See key details
- FDA cause
- Labeling design
What is being recalled?
Amplatzer Amulet Left Atrial Appendage Occluder Model Numbers 1. 9-ACP2-007-016 2. 9-ACP2-007-018 3. 9-ACP2-007-020 4. 9-ACP2-007-022 5. 9-ACP2-010-025 6. 9-ACP2-010-028 7. 9-ACP2-010-031 8. 9-ACP2-010-034
The retrieved code information does not contain explicit model/GTIN pairs that this publication can reliably map.
Search FDA identifier text
Search a model, catalog, lot or UDI value exactly as printed in FDA’s product description or code information.
This search checks only the FDA product description and code information displayed on this page. It does not decode a UDI, normalize GTIN lengths or establish a relationship between separately listed codes.
FDA code information
UDI-DI 1. 00811806013459 2. 00811806013466 3. 00811806013473 4. 00811806013480 5. 00811806013497 6. 00811806013503 7. 00811806013510 8. 00811806013527 All lots/serial numbers.
Why was this product recalled?
Changes to Instructions for Use (IFU) for the device regarding risk of Pulmonary Artery Injury (PAI).
What actions did Abbott take?
US IFU was updated and is available via https://manuals.eifu.abbott as of September 4, 2026. The firm began notifying consignees of the updated IFU on September 10, 2026. Abbott asks that physician users continue to follow all procedural steps that have already been provided via training, and that are now included in the IFU, as presented below: " After the landing zone has been identified, assess the closest distance to the pulmonary artery. " A distance =1.5 mm represents significant risk for a pulmonary artery injury; a distance between 1.5 and 3.0 mm represents a theoretical risk for a pulmonary artery injury; and a distance >3.0 mm represents a lower risk for a pulmonary artery injury. " To reduce the risk of pulmonary artery injury, consider an alternative landing zone or device orientation when clinically appropriate and C.L.O.S.E. criteria can still be met. " If the risk of pulmonary artery injury cannot be adequately minimized, the physician should carefully consider whether to proceed with device implantation.
Read the manufacturer action recorded by FDARecall timeline
Recall initiated by firm
FDA notice posted
FDA classification recorded
FDA enforcement report date
Related FDA submissions
No submission number with an exact verified relationship is linked in the retrieved recall notice.
FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.
Source and update history
- FDA recall notice Z-0191-2027
- openFDA enforcement record · Source release Nov 11, 2026 · Retrieved Nov 19, 2026
- openFDA device recall record · Source release Nov 14, 2026 · Retrieved Nov 19, 2026
- FDA enforcement data
First stored snapshot of this source.
- FDA device-recall notice
First stored snapshot of this source.
The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.
Our data sources and methodology